These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 15996257)
61. Islet transplantation in patients with diabetes mellitus: choice of immunosuppression. Nanji SA; Shapiro AM BioDrugs; 2004; 18(5):315-28. PubMed ID: 15377174 [TBL] [Abstract][Full Text] [Related]
62. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039 [TBL] [Abstract][Full Text] [Related]
63. Protective effect of glucocorticoid-free immunosuppressive regimen in allogenic islet transplantation. Du CY; Xu EK Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):43-7. PubMed ID: 16481281 [TBL] [Abstract][Full Text] [Related]
64. Simple evaluation of engraftment by secretory unit of islet transplant objects for living donor and cadaveric donor fresh or cultured islet transplantation. Matsumoto S; Yamada Y; Okitsu T; Iwanaga Y; Noguchi H; Nagata H; Yonekawa Y; Nakai Y; Ueda M; Ishii A; Yabunaka E; Tanaka K Transplant Proc; 2005 Oct; 37(8):3435-7. PubMed ID: 16298620 [TBL] [Abstract][Full Text] [Related]
65. Calcineurin inhibitor-free immunosuppressive regimen in type 1 diabetes patients receiving islet transplantation: single-group phase 1/2 trial. Maffi P; Berney T; Nano R; Niclauss N; Bosco D; Melzi R; Mercalli A; Magistretti P; De Cobelli F; Battaglia M; Scavini M; Demuylder-Mischler S; Secchi A; Piemonti L Transplantation; 2014 Dec; 98(12):1301-9. PubMed ID: 25286053 [TBL] [Abstract][Full Text] [Related]
66. Clinical islet transplantation at the University of Alberta--the Edmonton experience. Truong W; Lakey JR; Ryan EA; Shapiro AM Clin Transpl; 2005; ():153-72. PubMed ID: 17424733 [TBL] [Abstract][Full Text] [Related]
67. Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity? Desai NM; Goss JA; Deng S; Wolf BA; Markmann E; Palanjian M; Shock AP; Feliciano S; Brunicardi FC; Barker CF; Naji A; Markmann JF Transplantation; 2003 Dec; 76(11):1623-5. PubMed ID: 14702535 [TBL] [Abstract][Full Text] [Related]
68. Use of Culture to Reach Metabolically Adequate Beta-cell Dose by Combining Donor Islet Cell Isolates for Transplantation in Type 1 Diabetes Patients. Lee D; Gillard P; Hilbrands R; Ling Z; Van de Velde U; Jacobs-Tulleneers-Thevissen D; Maleux G; Lapauw B; Crenier L; De Block C; Mathieu C; Pipeleers D; Keymeulen B Transplantation; 2020 Oct; 104(10):e295-e302. PubMed ID: 32433237 [TBL] [Abstract][Full Text] [Related]
69. Long-Term Follow-Up of the Edmonton Protocol of Islet Transplantation in the United States. Brennan DC; Kopetskie HA; Sayre PH; Alejandro R; Cagliero E; Shapiro AM; Goldstein JS; DesMarais MR; Booher S; Bianchine PJ Am J Transplant; 2016 Feb; 16(2):509-17. PubMed ID: 26433206 [TBL] [Abstract][Full Text] [Related]
71. Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin. van de Linde P; Vd Boog PJ; Tysma OM; Elliott JF; Roelen DL; Claas FH; de Fijter JW; Roep BO Clin Exp Immunol; 2007 Jul; 149(1):56-62. PubMed ID: 17459076 [TBL] [Abstract][Full Text] [Related]
72. Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression. Lee D; Keymeulen B; Hilbrands R; Ling Z; Van de Velde U; Jacobs-Tulleneers-Thevissen D; Maleux G; Lapauw B; Crenier L; De Block C; Mathieu C; Pipeleers D; Gillard P Transplantation; 2017 Sep; 101(9):2218-2227. PubMed ID: 27779572 [TBL] [Abstract][Full Text] [Related]
73. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Sarwal MM; Vidhun JR; Alexander SR; Satterwhite T; Millan M; Salvatierra O Transplantation; 2003 Nov; 76(9):1331-9. PubMed ID: 14627912 [TBL] [Abstract][Full Text] [Related]
74. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Froud T; Faradji RN; Pileggi A; Messinger S; Baidal DA; Ponte GM; Cure PE; Monroy K; Mendez A; Selvaggi G; Ricordi C; Alejandro R Transplantation; 2008 Jul; 86(1):36-45. PubMed ID: 18622276 [TBL] [Abstract][Full Text] [Related]
75. ET-Kyoto ductal injection and density-adjusted purification combined with potent anti-inflammatory strategy facilitated single-donor islet transplantation: case reports. Matsumoto S; Noguchi H; Takita M; Shimoda M; Tamura Y; Olsen G; Naziruddin B; Onaca N; Levy MF Transplant Proc; 2010; 42(6):2159-61. PubMed ID: 20692433 [TBL] [Abstract][Full Text] [Related]
76. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Sarwal MM; Yorgin PD; Alexander S; Millan MT; Belson A; Belanger N; Granucci L; Major C; Costaglio C; Sanchez J; Orlandi P; Salvatierra O Transplantation; 2001 Jul; 72(1):13-21. PubMed ID: 11468528 [TBL] [Abstract][Full Text] [Related]
77. Long-term graft function after allogeneic islet transplantation. Lakey JR; Kin T; Warnock GL; Shapiro AM; Tsapogas P; Imes S; Korbutt GS; Kneteman NM; Rajotte RV; Ryan EA Cell Transplant; 2007; 16(4):441-6. PubMed ID: 17658134 [TBL] [Abstract][Full Text] [Related]